With a comprehensive agenda encompassing four distinct yet related programs - Modulating the Tumour Microenvironment, Next Generation Cell-Based Immunotherapies, Bispecific and Multi-specific Antibody Therapeutics and Therapeutic Cancer Vaccines, the Summit promises to be a forum for the exchange of cutting-edge research, and a platform for collaboration among the global immuno-oncology community.

Highlights include a plenary keynote session featuring 2 distinguished speakers; engaging breakout discussions that bring peers together to chat about the most pressing or contentious topics; a balanced faculty of industry and academia speakers; posters showcasing innovative studies and an Exhibit Hall gathering the technology leaders in the IO space.

The NCI RNA Biology Initiative aims to facilitate the rapid exchange of information and expertise on the structure, function, biological roles, and therapeutic uses of RNA. Our goal is to foster synergistic interactions amongst NIH investigators and between NIH investigators and the larger scientific community. We anticipate that new insights into RNA biology and the development of innovative RNA-based tools and therapies will both define novel targets and accelerate the implementation of therapeutic interventions in cancer.

This one-day workshop will bring together leaders from industry, academia, and government with expertise in therapeutic oligonucleotides, delivery, small molecules, and preclinical development of novel RNA-based and RNA-targeted therapies.

"The thymus: from biology to medicine and back"

PROGRAM COMMITTEE CHAIRS

Keith T. Flaherty, Harvard Medical School, Boston, Massachusetts
Christina Curtis, Stanford University, Stanford, California

The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.

More information about the AACR Annual Meeting 2024 will be available online and in the Call for Abstracts in late August 2023.

This conference will cover new scientific areas that bring together aspects of cancer biology and immunity that are often only discussed at separate specialized meetings. The presence of both basic and clinical investigators will expose the participants to these new concepts and provide an opportunity to discuss and explore the clinical translation of this rapidly emerging new understanding of cancer immunobiology.

Organizers: James Allison, Andrea Schietinger, Antoni Ribas, and Padmanee Sharma.

This meeting brings together scientists and clinicians from many aspects of tumor immunology to rethink the next steps in the evolution of cancer immunotherapy. It is expected to provide a springboard toward basic science discoveries and new, more effective therapies.

IMPORTANT DATES

Registration Site Opens: August 2023

Abstract Submission Site Opens: Sept. 15, 2023

Abstract Submission Site Closes: Jan. 10, 2024

Early Registration and Housing Deadline: Feb. 12, 2024

ESMO TAT offers participants a glimpse into the future of anticancer therapies, focusing on promising new targets and agents with a particular emphasis on early drug development. Speakers from both academia and industry will participate in an expanded program, including four new joint ESMO-Industry special sessions addressing drug development, methodological, regulatory, strategic financing and investment issues, offering attendees a fresh, wide-ranging perspective on the development of innovative cancer therapeutics and their optimal implementation.

The 2024 Advanced Course in Basic & Clinical Immunology will be held February 4-February 7, 2024, in La Jolla, California. 16 course lectures from renowned faculty presented a clinical spin on major topics in cellular and molecular immunology.

The lectures, delivered by talented faculty who are renowned ability to span basic and clinical science, take attendees from the bench to the bedside and back again.

Tailored to early-to-mid career scientists and clinicians in the field of cancer immunotherapy working in academic, clinical, industry and government settings, this hybrid program provides the best in cancer immunotherapy education taught by leading experts in the field.

Winter School participants gain a deep understanding of the core principles of tumor immunology and cancer immunotherapy, and developing areas in the field including biomarker technology, validation and clinical integration, clinical trial design, data analysis and considerations for combination therapies.

Via its small size with 24 early-career researchers, the Winter School is designed to offer participants an extraordinary development experience among peers and leaders in a beautiful setting. The relaxed, yet comprehensive program and involvement of supportive leaders in the field provide participants with one-on-one learning and networking opportunities.

Submit your application by October 23, 2023.

The Leipzig Immune ONcology (LION) Conference will focus on the latest developments in immune oncology and provide a forum for leading scientists, clinicians, and industry professionals to exchange ideas and discuss new findings in this exciting field. You are invited to submit your abstracts for oral and poster presentations at the conference. In addition to a stimulating scientific program, the conference will feature networking opportunities, including a welcome reception and poster sessions, as well as an industry exhibition showcasing the latest technologies and services related to cancer immunotherapy research. The LION Conference is organized by the Fraunhofer Institute for Cell Therapy and Immunology IZI and the University Hospital Leipzig.

It will review tumor immunology as the scientific foundation for the current practice of cancer immunotherapy, emphasizing fundamental principles, recent clinical advances, current limitations, and near-term opportunities for further accelerating clinical progress.

Summit4CI 2023 is taking place in Ottawa, Ontario at the Fairmont Château Laurier, Sunday, October 1 - Wednesday, October 4. The summit will explore the latest progress in cancer immunotherapy from scientific, clinical, industry and patient perspectives during BioCanRx’s seventh scientific conference. Summit4CI will feature internationally recognized speakers, networking and social events, an HQP Development Day, scientific presentations, poster sessions, a public forum, a debate, and more.

SCIENTIFIC PLANNING COMMITTEE

Mustafa Diken, Johannes Gutenberg University, Mainz, Germany
Marina Garassino, University of Chicago, Chicago, Illinois, USA
Nir Hacohen, Broad Institute of MIT and Harvard; Massachusetts General Hospital, Boston, Massachusetts, USA
Susan M. Kaech, The Salk Institute for Biological Studies, La Jolla, California, USA
Paola Nisticò, Regina Elena National Cancer Institute, Rome, Italy
Pamela S. Ohashi, University of Toronto, Toronto, ON, Canada
Catherine Sautès-Fridman, University Paris-Descartes, Paris, France
Andrea Schietinger, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Özlem Türeci, BioNTech SE, Mainz, Germany
Cassian Yee, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Laurence Zitvogel, Gustave Roussy Institute, Villejuif, France